Gilead ETF sales totaled $30.4 million net on October 23, 2026, as funds selling the biopharmaceutical company’s shares made larger transactions than those buying. AVLV was the largest seller, exiting its position.

Key Takeaways

  • Twenty-nine ETFs added Gilead shares, while 14 reduced their holdings.
  • AVLV sold 181,408 shares valued at $28.3 million and held none afterward.
  • The session marked the fourth consecutive reported day of net ETF selling.

Gilead ETF sales led by AVLV

AVLV’s exit was the largest reported reduction by dollar value. SPY and XLV were the next-largest sellers, but both retained substantial positions in Gilead Sciences, whose shares trade under the ticker GILD.

Although more funds bought than sold, the larger reductions outweighed the purchases. The holdings data do not establish why the funds traded or whether investors withdrew money from them.

ItemDetails
AVLVSold 181,408 shares for $28.3 million; no shares remained.
SPYSold 67,398 shares for $10.5 million; retained 15,190,415 shares.
XLVSold 47,964 shares for $7.5 million; retained 8,903,786 shares.
IBBSold 17,121 shares for $2.7 million; retained 5,878,634 shares.

Four days of net selling followed purchases

ETF holdings changes showed net selling of $19.3 million on October 20, $17.0 million on October 21 and $2.8 million on October 22, before the $30.4 million figure on October 23.

That run followed net purchases of $58.2 million on October 19. The figures describe changes in ETF holdings, not a measure of Gilead’s share-price movement.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.